- E-mail : info_medicalmarketing@jindunmedical.com
- Phone : +86 21 64057580
- Address : Shanghai China
20 antihypertensive drugs sold well, and 4 domestic brands broke through!
A few days ago, the hypertensive chemical drug market was again surging. Three products, including valsartan amlodipine tablets (I) of Tianjin Lisheng Pharmaceutical and perindopril indapamide tablets of Jiangxi Shimei Pharmaceutical, were approved on the same day. Since this year, 32 hypertensive chemicals (71 product specifications) have been approved. According to the data from Mi Nei Wang, in 2021, the terminal hypertensive chemical drug market in China's urban drug stores will break through the 15 billion yuan mark, and it is expected to reach a new high in 2022, with three major and more than one billion products taking the lead, and four domestic brands on the top 20. Up to now, nearly 70 hypertensive drugs (more than 270 acceptance numbers) have been reported for production and under review in new categories. Zhengda Tianqing Pharmaceutical Group, Chengdu Beite Pharmaceutical and other companies have made the first attempt. The dry suspension of amlodipine benzoate of Guangzhou Yipinhong Pharmaceutical and the tablets of alisartan and amlodipine of Shenzhen Xinlitai Pharmaceutical are improved new drugs, which are expected to be the first in China.
-
date
2022-11-29
-
location
Shanghai, China
